India's pharmaceutical industry is characterized by expansion in research-and-development activities, rising product penetration into regulated markets, and by a widening array of products, says Indoco Remedies Chairman Suresh G. Kare. Kare says India's low-cost, high-standard pharmaceutical services are making India a center for contract research and manufacturing services (CRAMs) worldwide. He sees India's pharmaceutical market generating a total of $30 billion annually by 2010. Indoco specializes in manufacturing and marketing finished pharmaceutical products and active ingredients for regulated markets. Kare says global pharmaceutical companies are facing increasing research-and-development cost combined with falling productivity, and this is driving business to India and China. In terms of high standards, Kare notes that "India has the highest number of manufacturing plants approved by the U.S. FDA, in fact second only to the U.S." He adds that "the introduction of product patent in India has brought about some fundamental changes in strategies of the pharmaceutical companies, with focus shifting more towards R&D." (Click here for more
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.
